Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Periodic Interim
confidence 95%
filed 2026-08-12
This is a periodic interim financial report disclosing KEPCO's unaudited consolidated and separate results of operations for the first half of fiscal year 2026 (January–June 2026), prepared in accordance with K-IFRS. The filing presents condensed consolidated and separate statements of comprehensive income for both the second quarter and the six-month period, which is the standard format for a half-year interim report by a foreign private issuer. This is the periodic report itself, not a discrete event or press release announcing results.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-12
Item 2.02
Annexon reported second quarter 2026 financial results, including R&D expenses of $46.6M, G&A expenses of $10.6M, and a net loss of $55.3M ($0.28 per share), with a cash position of $209.2M and anticipated runway into 2028.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-12
Item 8.01
Annexon announced a strategic expansion of its Phase 3 ARCHER II trial for vonaprument by adding a Month 24 dual primary endpoint alongside the existing Month 15 endpoint, and launched an open-label extension study.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-08-12
EX-99.1
This is a press release announcing Pharvaris' second quarter 2026 financial results, including Q2 2026 cash position (€318 million), R&D expenses (€35.0 million), G&A expenses (€15.8 million), and net loss (€47.8 million or €0.70 per share). The document explicitly states "announced financial results for the second quarter ending on June 30, 2026" and includes a "Second Quarter 2026 Financial Results" section with key financial metrics. While the release also contains business updates on clinical trials and a corporate promotion, the primary disclosure is the quarterly financial results, which is material to investors assessing the company's financial position and burn rate.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-12
Item 2.02
Performance Food Group issued a press release on August 12, 2026 announcing fourth-quarter and full-year fiscal 2026 financial results, including net sales of $67.8 billion (up 7.2%), net income of $359.3 million (up 5.6%), and Adjusted EBITDA of $1,929.4 million (up 9.2%), along with fiscal 2027 guidance. This is a standard earnings release disclosure under Item 2.02 that would materially affect a reasonable investor's assessment of the company's financial performance and outlook.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-12
Item 2.02
Lexeo Therapeutics issued a press release on August 12, 2026 announcing financial results for the three and six months ended June 30, 2026, including net losses of $25.9M and $46.1M respectively, R&D expenses of $19.0M and $34.7M respectively, G&A expenses of $9.0M and $15.6M respectively, and a cash position of $234.2M, along with material clinical program updates including SUNRISE-FA 2 initiation and RMAT designation for LX2020.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-12
Item 2.02
TScan Therapeutics issued a press release on August 12, 2026, announcing its financial results for the second quarter ended June 30, 2026, including revenue of $1.1 million, R&D expenses of $23.4 million, net loss of $30.4 million, and cash position of $100.2 million. The disclosure is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, with detailed financial statements and operational highlights. This is material to investors assessing the company's financial condition and runway.
View raw filing on EDGAR →
8-K
Earnings release
confidence 94%
filed 2026-08-12
Item 2.02
Sutro Biopharma issued a press release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing revenue of $9.8 million, net loss of $38.5 million, and cash position of $164.3 million, along with early clinical data from the STRO-004 Phase 1 study.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-12
Item 2.02
This is a standard quarterly earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release (Exhibit 99.1) discloses financial results including collaboration and license revenue of $18.7 million, R&D expenses of $14.6 million, G&A expenses of $7.6 million, and a net loss of $6.4 million for the quarter, along with condensed consolidated balance sheets and statements of operations. The disclosure is material as it provides investors with the company's quarterly financial performance and cash runway guidance into Q1 2028.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-12
EX-99.4
This is a press release announcing Boyd Group Services Inc.'s second quarter 2026 financial results. The exhibit discloses quarterly sales of $1,013.7 million (up 29.9% year-over-year), Adjusted EBITDA of $135.9 million (up 44.9%), and Adjusted EBITDA margins expanding to 13.4% from 12.0%. The document includes detailed financial and operational highlights, management commentary from the CEO, and forward-looking guidance—all hallmarks of a quarterly earnings release. Material to investors as it reports significant revenue growth, margin expansion, and synergy realization from the Joe Hudson's acquisition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-12
Item 5.02
The filing discloses the appointment of Scott Colangelo to the Board of Directors effective August 11, 2026, and his concurrent appointment to the Audit Committee. The principal disclosed action is a person taking a role as director, which is the core event under Item 5.02(d). While the disclosure mentions standard director compensation arrangements, the focus is on the appointment itself rather than compensation terms, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-12
Item 5.02
Lei Z. Schlitz resigned from her position as a director of Archer-Daniels-Midland Company, effective December 31, 2026, due to a voluntary material change in her principal employment. The disclosure centers on the departure of a director from the Board, which is a material governance event affecting the composition of the company's leadership.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-12
Item 8.01
Illumina entered into an Underwriting Agreement on August 10, 2026 for the issuance and sale of $300,000,000 aggregate principal amount of 4.950% notes due 2029. The company expects to use net proceeds to repay existing 4.650% notes due September 9, 2026. This is a material debt issuance creating a new direct financial obligation, disclosed under Item 8.01 (Other Events).
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-12
Item 2.02
This is a clear earnings release disclosing Avalyn Pharma's financial results for Q2 2026 (ended June 30, 2026), including R&D expenses ($24.7M), G&A expenses ($6.6M), net loss ($28.9M), and cash position ($413.5M). The press release is furnished as Exhibit 99.1 and includes condensed consolidated financial statements and balance sheet data, which are typical of quarterly earnings announcements. Material to investors assessing the company's financial condition and cash runway.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-12
Item 2.02
The filing discloses flyExclusive's financial results for Q2 2026 and the first half of 2026 through a corporate presentation furnished as Exhibit 99.1. The presentation contains detailed financial metrics including consolidated revenue of $111 million (+22% YoY), gross profit growth of +65% YoY, and positive Adjusted EBITDA of $4.2M with a +954 basis point margin improvement. This is a classic earnings release disclosure under Item 2.02, presenting quarterly and year-to-date operating results and performance metrics to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-12
Item 2.02
This is a clear earnings release disclosing Spruce Biosciences' financial results for Q2 2026 and the first six months of 2026, including cash position ($96.3M), R&D expenses ($12.2M for Q2), G&A expenses ($4.3M for Q2), and net loss ($16.2M for Q2, or $(6.68) per share). The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes both financial statements (condensed balance sheet and statements of operations) and material corporate updates regarding TA-ERT development milestones and leadership appointments.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-12
Item 5.02
Janet Lee, serving as General Counsel and Corporate Secretary, is departing her officer role effective December 31, 2026 or upon appointment of a successor. Although she will transition to an advisory role through June 30, 2027, the principal disclosed action is her departure from the General Counsel and Corporate Secretary positions, which are material officer roles. This is a clear executive departure under Item 5.02.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-08-12
Item 1.01
The filing discloses Amendment No. 1 to an existing Credit Agreement dated February 12, 2026, which modifies the terms of senior secured term loan facilities totaling approximately $1.52 billion (TLA Facility of $745.3M and TLB Facility of $773.1M). While this is technically an amendment to existing debt rather than a new issuance, the material modification of interest rate spreads (0.75% reduction on TLA, 0.50% on TLB) and other terms constitutes a material change to the Company's direct financial obligations. The Item 1.01 classification and the emphasis on the amendment's substantive terms support classification as a debt-related event; however, the amendment nature (rather than new issuance) creates some ambiguity about whether this is best characterized as debt_issuance or financial_other.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-08-12
Item 1.01
BCP Investment Corp amended its senior secured revolving credit facility with KeyBank, doubling the facility amount from $75.0 million to $150.0 million, extending the maturity date to August 6, 2031, and reducing the applicable margin. Concurrent with this amendment, the company refinanced an existing JPMorgan facility by using proceeds from the amended KeyBank facility to repay all outstanding amounts.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 85%
filed 2026-08-12
Item 5.07
The filing discloses the results of the 2026 annual meeting of stockholders held on August 11, 2026, which is the core purpose of Item 5.07. Although the meeting was adjourned due to lack of quorum before voting could occur on director elections and auditor ratification, the disclosure of this outcome—including the consequence that incumbent directors will serve as holdovers under Maryland law—constitutes a shareholder vote result (or in this case, the failure to achieve one). This is material because it affects governance continuity and director accountability to shareholders.
View raw filing on EDGAR →
8-K
Bankruptcy Filing
confidence 99%
filed 2026-08-12
Item 7.01
Sangamo Therapeutics filed a voluntary Chapter 11 petition on June 23, 2026 (Case No. 26-10989), and this 8-K Item 7.01 discloses the filing of its monthly operating report for the bankruptcy case. The disclosure explicitly states the company "filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code" and notes the company's stock has been delisted from Nasdaq and is trading on the OTC market under "SGMOQ." This is a terminal event materially threatening the registrant's continued existence.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-12
Item 8.01
Intel announced and entered into an underwriting agreement for a $20 billion registered public offering of approximately 210.5 million shares of common stock at $95 per share, with underwriters holding a 30-day option to purchase an additional 31.6 million shares. Net proceeds of approximately $19.7 billion are intended for general corporate purposes including capital expenditures and working capital.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-12
Item 2.02
Lumexa Imaging disclosed second quarter 2026 financial results via press release, reporting consolidated revenues of $264.2 million (5.1% increase year-over-year), net income of $2.7 million compared to a prior-year loss of $7.2 million, and updated full-year 2026 guidance.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-12
Item 2.03
American Airlines entered into a Note Purchase Agreement on August 10, 2026, providing for the issuance of $1,325,382,000 in equipment notes secured by aircraft, consisting of Series A notes at 5.70% and Series B notes at 6.30%, with principal payments commencing in February 2027 and final maturity between 2035 and 2039.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-12
Item 7.01
PGE disclosed a stipulation with Oregon's Public Utility Commission Staff approving a corporate reorganization to create a holding company structure, subject to OPUC final approval on August 25, 2026. This is a material strategic and operational restructuring involving significant regulatory commitments ($45 million in customer credits and community investments), restrictions on subsidiary funding, capital structure requirements (45% common equity minimum), and a "Golden Share" governance mechanism. While the holding company formation is a significant corporate event, it does not fit the specific M&A taxonomy (ma_activity applies to acquisitions/dispositions/mergers, not internal reorganizations) and is best classified as a material operational restructuring with governance implications.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-12
Item 5.02
Anthony Aliquo was appointed Chief Accounting Officer and principal accounting officer effective August 10, 2026, representing a material promotion from Vice President, Controller. While the filing also discloses that Fred Ahlholm ceased serving as principal accounting officer (a secondary change), the principal disclosed action centers on Aliquo's appointment to a named executive officer role. The appointment is accompanied by salary and bonus increases, confirming its significance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-12
Item 8.01
Delek Logistics announced commencement of an underwritten public offering of $175 million of common units (with an additional $26.25 million option), representing limited partner interests in the partnership. This is a material equity issuance that will dilute existing unitholders. The proceeds are intended to repay debt and for general partnership purposes, which is typical for capital raises by MLPs.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-12
Item 2.02
Spire Global issued a news release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, including Q2 2026 revenue of $18.0 million, net loss of $20.0 million, and adjusted EBITDA of ($8.6) million, along with full-year 2026 revenue guidance of $75.0–$85.0 million. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the news release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes quarterly financial metrics, year-over-year and sequential comparisons, and forward-looking guidance, all hallmarks of a quarterly earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-12
Item 2.02
Andersen Group Inc. issued a press release announcing financial results for the second quarter and six months ended June 30, 2026, reporting revenue of $217.7 million (Q2) and $458.4 million (six months), with adjusted net income of $39.0 million (Q2, up 38.8% YoY), and provided full-year 2026 guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-12
Item 2.02
This is a clear earnings release disclosing Sera Prognostics' second quarter 2026 financial results, including revenue ($30,000), operating expenses ($10.0 million), and net loss ($9.1 million), along with condensed financial statements and business highlights. The filing explicitly states the press release was issued on August 12, 2026, announcing Q2 2026 results and is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-12
Item 2.02
Harmonic issued a press release on August 12, 2026 disclosing preliminary unaudited financial results for Q2 2026 (quarter ended July 3, 2026), including net revenue of $173.0 million, operating profit, and earnings per share. The company also raised its full-year 2026 outlook for Broadband revenue to $505-$525 million. This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-12
Item 2.02
This is a classic earnings release disclosure under Item 2.02. The company announced second quarter 2026 financial results on August 12, 2026, including net loss of $9.6 million (vs. $1.7 million in Q2 2025), zero revenue (vs. $14.2 million in Q2 2025), and detailed operating expense breakdowns. The press release is furnished as Exhibit 99.1 and includes condensed consolidated balance sheet and statements of operations. While the filing also covers business highlights (SP001 license agreement, Utebzi FDA approval, royalty financing, and CMO appointment), the Item 2.02 section is explicitly focused on financial results for the quarter ended June 30, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-12
Item 2.02
This is a clear earnings release disclosing Kura Oncology's second quarter 2026 financial results, including net product revenue of $9.1 million, collaboration revenue of $11.8 million, R&D expenses of $61.9 million, and a net loss of $68.3 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes detailed financial statements and operational metrics for the quarter ended June 30, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-12
Item 2.02
Atara Biotherapeutics disclosed second quarter 2026 financial results on August 12, 2026, including revenue of $0.6 million, net loss of $4.8 million (or $0.32 loss per share), and cash position of $9.9 million. The press release titled "Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress" is furnished as Exhibit 99.1, with detailed condensed consolidated balance sheets and statements of operations. This is a standard quarterly earnings release disclosing material financial results and cash runway guidance into mid-2027.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-12
Item 2.02
Acrivon issued a press release on August 12, 2026 announcing financial results for the quarter ended June 30, 2026, including net loss of $17.964 million, R&D expenses of $13.844 million, and cash position of $90.0 million as of June 30, 2026. The filing includes condensed consolidated statements of operations and balance sheets, which are typical of a quarterly earnings disclosure. This is a standard Item 2.02 earnings release for a clinical-stage biotech company.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-08-12
Item 2.02
Coherent Corp. disclosed financial results for Q4 and full year fiscal 2026 ended June 30, 2026, reporting revenue of $2.05B (up 34% Y/Y), GAAP EPS of $1.19 (up $2.02 Y/Y), and non-GAAP EPS of $1.74 (up $0.74 Y/Y), along with forward guidance for Q1 FY2027.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-12
Item 3.01
Generation Income Properties received a Nasdaq delisting notice for failing to maintain the minimum $1.00 bid price for 30 consecutive business days and failing the minimum $1.0 million market value of publicly held shares requirement. The company has regained compliance with the minimum stockholders' equity rule ($2.5M) but is now subject to a mandatory one-year panel monitor, during which any future non-compliance will result in automatic delisting with no opportunity to submit a compliance plan.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-12
Item 2.02
This is a clear earnings release disclosing Atea's financial results for Q2 2026 (three and six months ended June 30, 2026), including operating expenses, net loss, cash position, and per-share metrics. The press release, furnished as Exhibit 99.1, announces "financial results for the second quarter ended June 30, 2026" alongside a business update on clinical trial progress. The financial tables show condensed consolidated statements of operations and balance sheet data, which are hallmarks of an earnings disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-12
Item 1.01
ACRES Commercial Realty Corp. entered into a Securities Purchase Agreement on August 10, 2026, to issue 2,220,000 shares of Series C Cumulative Redeemable Preferred Stock at $23.75 per share, generating approximately $52.75 million in gross proceeds. Although the offering was registered (via Form S-3), the issuance of preferred stock with fixed-to-floating dividend terms represents a material capital raise that dilutes existing equity holders and signals the company's need to raise capital. This is a material event affecting the registrant's capital structure and financial position.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-12
Item 2.02
RenovoRx issued a press release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 revenue of $909,000 (61% sequential growth, 115% year-over-year growth), gross profit of $766,000 (84% margin), net loss of $2.9 million, and raising full-year 2026 revenue guidance to $3.75M–$4.25M. This is a standard quarterly earnings release with detailed financial statements and operational metrics, clearly falling under Item 2.02 disclosure of results of operations and financial condition.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-12
Item 8.01
American Healthcare REIT closed a public offering of 13,250,000 shares of common stock on August 12, 2026, structured as a forward sale with underwriters borrowing and selling shares to hedge forward purchasers' obligations. The filing explicitly states the company intends to contribute net proceeds to its operating partnership for a pending acquisition of senior housing properties and general corporate purposes. This is a material equity issuance that will dilute existing shareholders and fund significant capital deployment.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-08-12
Item 1.01
AEVEX Corp. entered into a definitive Agreement and Plan of Reorganization on August 12, 2026, to acquire Maritime Applied Physics Corporation (BlackSea Technologies) for up to $650 million in total consideration ($250 million cash, $350 million in stock, and $50 million in contingent earnout). The transaction, expected to close in September 2026, materially expands AEVEX's multi-domain autonomous systems capabilities and is subject to customary closing conditions including HSR antitrust clearance and NYSE approval.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-12
Item 2.02
First Tracks issued a press release on August 12, 2026 announcing financial results for the three and six months ended June 30, 2026, including cash position ($168.0 million), R&D expenses ($25.6M and $59.6M), G&A expenses ($9.3M and $28.1M), and net loss ($33.4M and $83.9M). The filing explicitly states this is Item 2.02 disclosure with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes both financial statements and operational updates on clinical trial progress.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-12
Item 2.02
Identiv issued a press release on August 12, 2026 announcing financial results for Q2 2026 ended June 30, 2026, disclosing revenue of $5.7 million, GAAP net loss of ($4.7) million, and non-GAAP adjusted EBITDA loss of ($2.7) million. The filing explicitly states "On August 12, 2026, Identiv, Inc. (the "Company") issued a press release announcing financial results for its second quarter ended June 30, 2026" and attaches the press release as Exhibit 99.1, which is the standard format for earnings releases under Item 2.02.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 98%
filed 2026-08-12
Item 1.01
Martin Marietta entered into an underwriting agreement on August 11, 2026, to issue $5.5 billion in aggregate principal amount of senior notes across five tranches (2029, 2032, 2034, 2036, and 2056 maturities) with interest rates ranging from 4.850% to 6.375%. The proceeds are earmarked to fund the acquisition of Lhoist North America.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-12
Item 2.02
This is a clear earnings release for Q2 2026 ended June 30, 2026. Item 2.02 discloses Marchex's financial results including revenue of $11.0 million, net loss of $0.4 million, and adjusted EBITDA of $0.7 million, with the full earnings release furnished as Exhibit 99.1. The filing includes consolidated statements of operations and balance sheets, pro forma combined results following the Archenia acquisition, and forward-looking financial guidance for Q3 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-12
Item 2.02
This is a clear earnings release disclosing Kailera's financial results for Q2 2026 (quarter ended June 30, 2026), filed on August 12, 2026. The press release reports R&D expenses of $101.1 million, G&A expenses of $20.3 million, and a net loss of $111.3 million for the quarter, along with cash position of $1,171.8 million. The disclosure includes both financial results and material business updates regarding clinical trial progress and executive appointments, which are typical components of a quarterly earnings release.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-12
Item 8.01
State Street issued and sold 500,000 depositary shares representing preferred stock (Series L Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock) in a public offering, raising approximately $495.7 million in net proceeds. Although technically equity in form, perpetual preferred stock functions as a debt-like instrument with fixed rates and liquidation preferences, and is classified as a direct financial obligation. This is a material capital-raising event disclosed under Item 8.01.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-12
Item 2.02
Leslie's issued a press release on August 12, 2026 announcing third quarter 2026 financial results for the period ended July 4, 2026, with detailed disclosure of sales ($458.5M, down 8.4%), gross profit, net income, EPS, and Adjusted EBITDA. The filing explicitly states the press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes both quarterly and nine-month results with year-over-year comparisons.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-12
This is a quarterly earnings release for 2Q26 (ended June 30, 2026) disclosing consolidated financial results including revenue of Ps. 26,037 million (38.7% growth), EBITDA of Ps. 960 million, and operational metrics such as 155 net new stores opened and same-store sales growth of 20.0%. The document explicitly states "2Q26 EARNINGS RELEASE" and presents detailed financial statements, management commentary, and cash flow analysis typical of a quarterly results announcement.
View raw filing on EDGAR →